- Report
- October 2024
- 186 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- March 2025
- 144 Pages
Global
From €2862EUR$2,999USD£2,398GBP
- Report
- March 2025
- 194 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- August 2024
- 175 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- February 2025
- 150 Pages
Global
From €4629EUR$4,850USD£3,878GBP
- Report
- May 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- March 2023
- 185 Pages
Global
From €4247EUR$4,450USD£3,558GBP
- Report
- May 2023
- 147 Pages
Global
From €4723EUR$4,949USD£3,957GBP
- Report
- March 2025
- 50 Pages
Global
From €2529EUR$2,650USD£2,119GBP
Gallium-67 is a radioactive isotope used in Nuclear Medicine and Radiopharmacology. It is used in imaging and therapeutic applications, such as the detection of tumors and the treatment of certain types of cancer. Gallium-67 is produced in nuclear reactors and cyclotrons, and is then purified and formulated into radiopharmaceuticals. These radiopharmaceuticals are used in imaging and therapeutic procedures, and are administered to patients intravenously.
Gallium-67 is a valuable tool in the diagnosis and treatment of cancer, and is used in many countries around the world. It is also used in research and development, as well as in the production of other radiopharmaceuticals.
Companies in the Gallium-67 market include GE Healthcare, Mallinckrodt Pharmaceuticals, Bracco Diagnostics, and Lantheus Medical Imaging. Show Less Read more
